India, Nov. 17 -- Greenwich LifeSciences, Inc. (GLSI) shares are up 23 percent, gaining $3.16 to $16.92 on Tuesday, after the company announced that two abstracts from its Phase III FLAMINGO-01 breast cancer immunotherapy trial have been accepted for publication at the 2026 San Antonio Breast Cancer Symposium or SABCS.

GLSI is currently trading at $16.92, up from the previous close of $13.76 on the Nasdaq. The stock has traded between $15.73 and $19.28 during the session, with volume of approximately 756,452 shares, compared with an average volume of 130,240. Its 52-week range is $7.78 to $34.10.

googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });

The company said two FLAMINGO-01 posters will be presented...